Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors. 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 14-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).

 

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVXD-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv

GeoVax announced that it has been nominated for the 2019 ViE (Vaccine Industry Excellence) Awards in three categories. Please use the following link to vote for these special industry awards in the follow categories:

https://www.surveymonkey.co.uk/r/J39ZFW3

• Best Vaccine Technology/Platform
• Best Therapeutic Vaccine
• Best Prophylactic Vaccine
  

GeoVax's development programs are importantly focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please read to our most recent Quarterly Update dated November 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

 

 

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

Crystal Research Associates has released a 17-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The report is available for download.

 

 

Snapshot of GeoVax

GeoVax Labs is  developing preventative and therapeutic human vaccines against infectious diseases and cancer. The Company’s patented Modified Vaccinia Ankara Virus-Like Particle (MVA-VLP) technology is the foundation for producing non-infectious virus-like particles (VLPs) from the cells of the individual receiving the vaccine. Producing VLPs in a vaccinated individual mimics a natural infection, stimulating both the humoral and cellular arms of the immune system to recognize, prevent, and control the target infection should it appear, while maintaining the safety characteristics of a replication-defective vector.

GeoVax is focused on developing vaccines against hemorrhagic fever (HF) viruses (Ebola, Sudan, Marburg, and Lassa), Zika virus (ZIKV), malaria, and human immunodeficiency virus (HIV). The Company also has programs to develop a vaccine to treat chronic Hepatitis B virus (HBV) infection and to apply its MVA-VLP technology to cancer immunotherapy (immuno-oncology). Furthermore, GeoVax is collaborating with Emory University to develop a therapeutic vaccine for human papillomavirus (HPV) infection, with a specific focus on head and neck cancer (HNC). GeoVax believes its expertise is complementary to a range of other human diseases for which there is an unmet medical need, and thus, has plans to expand its pipeline.

GeoVax was the winner of the 2018 “Best Biotech” Vaccine Industry Excellence Awards, a finalist for the 2018 “Best Prophylactic Vaccine” Award for its Zika vaccine at the World Vaccine Congress, and a finalist for Pipelines of Promise at Buzz of BIO 2018.

Key Points

• On November 8, 2018, GeoVax issued an overview of its R&D programs as well as reported its financial results for the quarter ended September 30, 2018.

• During the quarter, GeoVax announced that the U.S. Department of Defense (DoD) had awarded the Company a $2.4 million cooperative agreement in support of its novel Lassa Fever (LF) vaccine development program. This followed a Fast-Track Phase I/II SBIR grant award in April 2018 from the National Institutes of Health (NIH) with an expected budget of up to $1.9 million.

• In November 2018, the Company announced the start of a collaboration to develop a therapeutic vaccine for human papillomavirus (HPV) infection. The collaboration is to include preclinical animal testing of GeoVax’s MVA-vectored HPV vaccine candidates in combination with Swiss-based Virometix’ synthetic HPV vaccine candidate.

• The Company further began a collaboration with Vaxeal Holding SA, expanding its cancer vaccine program to include the design, construction, characterization, and animal testing of vaccine candidates using GeoVax’s MVA-VLP vaccine platform with Vaxeal’s proprietary designed genetic sequences. This project is complementary to the ongoing collaboration with ViaMune for co-developing cancer immunotherapies. In parallel, GeoVax is collaborating with the University of Pittsburgh and their Distinguished Professor, Dr. Olja Finn, using combined technologies for abnormal MUC1-expressing tumors.

• The Company’s collaboration with American Gene Technologies International, Inc. (AGT) for use of GeoVax’s vaccine in combination with AGT’s gene therapy to develop a functional cure for HIV is on track to enter a Phase 1 trial sponsored by AGT. AGT expects the trial to begin during the first quarter of 2019. In October 2018, positive results from the HVTN 114 (the Phase 1 trial of GeoVax’s preventive HIV vaccine) were presented at the HIVR4P conference in Madrid, Spain.

• The Company will be represented at the following upcoming conferences: Fourth International Conference on Vaccines Research and Development, Baltimore, Nov. 12-14 and World Vaccine & Immunotherapy Congress, San Diego, Nov. 28-30.

• At September 30, 2018, GeoVax reported cash balances of $511,242 versus $312,727 at December 31, 2017.

 *******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Topics: immunotherapy, Ebola, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv, Sudan, Marburg

GeoVax Labs, Inc. announced today the publication of a manuscript entitled “HIV/AIDS Vaccines: 2018,” authored by Harriet L. Robinson, PhD, GeoVax’s Director of HIV Vaccines and Chief Scientific Officer Emeritus. The paper is published in the peer-reviewed journal Clinical Pharmacology & Therapeutics, a journal of the American Society for Clinical Pharmacology & Therapeutics (ASCPT), and can be viewed at https://ascpt.onlinelibrary.wiley.com/doi/10.1002/cpt.1208. Dr. Robinson provides a comprehensive review of progress toward development of an HIV/AIDS vaccine in the article, including key challenges and lessons learned from completed efficacy trials. 

Despite development of effective antiretroviral therapies (ART), only 49% and 48% of people living with HIV in the U.S. and worldwide, respectively, have drug-controlled infections. Patients without drug-controlled infections develop AIDS and spread the infection. This indicates that for eliminating HIV, there is a need for an effective vaccine to be added to the arsenal of ART. Thus, only with a demonstrated effective HIV/AIDS vaccine can people worldwide avoid the infection, ongoing health risks, and societal impact resulting from this disease. GeoVax is a leader in developing a vaccine for the clade B subtype of HIV prevalent in the Western Hemisphere, Europe, and Japan. The Company's vaccine, GOVX-B11, is currently progressing in human clinical trials with the sponsorship of the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).”

GeoVax's development programs are focused on vaccines against HIV as well as Zika, hemorrhagic fever viruses (Ebola, Sudan, Marburg, Lassa), and malaria. GeoVax also is evaluating the use of its MVA-VLP platform in cancer immunotherapy and for therapeutic use in chronic Hepatitis B infections. .

For more information on GeoVax, please refer to our most recent Quarterly Update (https://bit.ly/2x4w4t8) dated August 14, 2018, as well as our Executive Informational Overview (EIO), issued on June 15, 2017 and available for download below.

 

 

*******************************************

Visit our Corporate Profile and Key Points pages

for the latest research on GeoVax Labs, Inc.

*******************************************

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, lassa, lasv

Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC). The report is available for download.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, hpv

Crystal Research Associates has issued a 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-OTC), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv